Literature DB >> 10819532

Screening and clinical implications for BRCA1 and BRCA2 mutation carriers.

S E Plon1.   

Abstract

In this article, we review the history of testing for mutations in breast cancer susceptibility genes and discuss the current state of testing for mutations in BRCA1 and BRCA2 in different clinical settings including at-risk individuals and cancer patients. The risk of breast cancer. other associated malignancies and prognosis in carriers of these mutations are reviewed. A final section includes discussion of current recommendations for surveillance and the need for further research to identify environmental and genetic factors which modify the risk of developing cancer in mutation carriers.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10819532     DOI: 10.1023/a:1018731914813

Source DB:  PubMed          Journal:  J Mammary Gland Biol Neoplasia        ISSN: 1083-3021            Impact factor:   2.673


  56 in total

1.  Prognosis of BRCA1 hereditary breast cancer.

Authors:  P Watson; J N Marcus; H T Lynch
Journal:  Lancet       Date:  1998-01-31       Impact factor: 79.321

2.  Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility, Adopted on February 20, 1996.

Authors: 
Journal:  J Clin Oncol       Date:  1996-05       Impact factor: 44.544

3.  Differential contributions of BRCA1 and BRCA2 to early-onset breast cancer.

Authors:  M Krainer; S Silva-Arrieta; M G FitzGerald; A Shimada; C Ishioka; R Kanamaru; D J MacDonald; H Unsal; D M Finkelstein; A Bowcock; K J Isselbacher; D A Haber
Journal:  N Engl J Med       Date:  1997-05-15       Impact factor: 91.245

Review 4.  Genetic testing: employability, insurability, and health reform.

Authors:  M A Rothstein
Journal:  J Natl Cancer Inst Monogr       Date:  1995

5.  Screening for 185delAG in the Ashkenazim.

Authors:  C S Richards; P A Ward; B B Roa; L C Friedman; A A Boyd; G Kuenzli; J K Dunn; S E Plon
Journal:  Am J Hum Genet       Date:  1997-05       Impact factor: 11.025

6.  Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium.

Authors:  D Ford; D F Easton; M Stratton; S Narod; D Goldgar; P Devilee; D T Bishop; B Weber; G Lenoir; J Chang-Claude; H Sobol; M D Teare; J Struewing; A Arason; S Scherneck; J Peto; T R Rebbeck; P Tonin; S Neuhausen; R Barkardottir; J Eyfjord; H Lynch; B A Ponder; S A Gayther; M Zelada-Hedman
Journal:  Am J Hum Genet       Date:  1998-03       Impact factor: 11.025

7.  Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene.

Authors:  S A Gayther; J Mangion; P Russell; S Seal; R Barfoot; B A Ponder; M R Stratton; D Easton
Journal:  Nat Genet       Date:  1997-01       Impact factor: 38.330

8.  Identification by representational difference analysis of a homozygous deletion in pancreatic carcinoma that lies within the BRCA2 region.

Authors:  M Schutte; L T da Costa; S A Hahn; C Moskaluk; A T Hoque; E Rozenblum; C L Weinstein; M Bittner; P S Meltzer; J M Trent
Journal:  Proc Natl Acad Sci U S A       Date:  1995-06-20       Impact factor: 11.205

9.  The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals.

Authors:  J P Struewing; D Abeliovich; T Peretz; N Avishai; M M Kaback; F S Collins; L C Brody
Journal:  Nat Genet       Date:  1995-10       Impact factor: 38.330

10.  Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.

Authors:  D F Easton; D Ford; D T Bishop
Journal:  Am J Hum Genet       Date:  1995-01       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.